The Current Role of Prostatic Acid Phosphatase and Prostate-Specific Antigen in the Management of Prostate Cancer by Shetty, Sugandh D. & Cerny, Joseph C.
Henry Ford Hospital Medical Journal 
Volume 40 Number 1 Article 22 
3-1992 
The Current Role of Prostatic Acid Phosphatase and Prostate-
Specific Antigen in the Management of Prostate Cancer 
Sugandh D. Shetty 
Joseph C. Cerny 
Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal 
 Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons 
Recommended Citation 
Shetty, Sugandh D. and Cerny, Joseph C. (1992) "The Current Role of Prostatic Acid Phosphatase and 
Prostate-Specific Antigen in the Management of Prostate Cancer," Henry Ford Hospital Medical Journal : 
Vol. 40 : No. 1 , 93-98. 
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol40/iss1/22 
This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has 
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health 
System Scholarly Commons. 
The Current Role of Prostatic Acid Phosphatase and Prostate-
Specific Antigen in the Management of Prostate Cancer 
Sugandh D. Shetty, MD,* and Joseph C. Cerny, MD* 
Cancer of the prostate (CAP) is the most common cancer in the American male with 132,000 new cases expected to be 
diagnosed in 1992 (1). It is also the second leading cause of can-
cer-related deaths with 34,000 men projected to die this year (1). 
Early diagnosis depends upon the availability of a sensitive and 
specific tumor marker. Prostatic acid phosphatase (PAP) has 
been used for staging and monitoring CAP for the last 50 years 
(2). Recently, with the development of prostate-specific antigen 
(PSA), interest in PAP has diminished considerably. 
Prostatic Acid Phosphatase 
PAP is a sialoglycoprotein, molecular weight 100,000 dal-
tons, secreted by the prostatic acinar cells (2). Ultrastructurally 
it is present in the lysosomes, secretory vacuoles, and golgi bod-
ies (3). PAP is secreted into the acinar and the ductal lumen and 
is present in high concentration in the ejaculate. Due to the large 
size ofthe PAP molecule, serum levels rise only after cancer has 
penetrated the prostate capsule Since its isolation in 1938 by 
Gutman and Gutman (4) and the demonstration of its respon.se 
to endocrine manipulation of prostate cancer by Huggins and 
Hodges (5), acid phosphatase has been extensively studied re-
garding its usefulness for early diagnosis, staging, and monitor-
ing CAP (2,6-12). However, because similar isoenzymes are 
present in virtually every tissue in the body, the nonspecificity 
ofthe PAP test has limited its diagnostic value. Even though ra-
dioimmunoassays are more sensitive than the former enzymatic 
assays, PAP values cannot be used reliably in screening (13). In 
addition to diurnal and individual variation, PAP levels rise af-
ter digital rectal examination (DRE), prostatic massage, cys-
toscopy, or transurethral resection of the prostate (2,14,15). 
Although testing for PAP has declined because of the avail-
ability of PSA, such tests were the best available means to moni-
tor patients with CAP for nearly five decades. Several studies 
have shown that in pathologically confirmed stage A and B dis-
ease (Table 1) PAP is in the normal range and patients with lo-
calized disease who had elevated PAP levels later developed 
bony metastasis (6-10). Thus, raised PAP levels can be used to 
predict extracapsular penetration even though 20% of patients 
with skeletal metastasis have normal values (2). tn assessing 
whether normal PAP predicts extracapsular extension, Bahnson 
and Catalona (11) studied 102 patients with surgically staged. 
clinically localized CAP and found that 22 (88%) of 25 patients 
whose PAP (enzymatic assay) was in the upper half of the nor-
mal range had stage C or D disease. By comparison, only 53% of 
77 patients with lower range of normal PAP had stage C or D 
disease. Similarly, Oesterling et at (12) reported that the rate of 
capsular penetration and seminal vesicle involvement was 11% 
and 0%, respectively, in patients whose PAP level was in the 
lower range of normal, compared to 50% capsular penetration 
and seminal vesicle involvement for patients in the upper nor-
mal range. In addition, PAP has been used to predict skeletal 
metastasis in patients being followed after radical prostatec-
tomy, radiotherapy, and hormonal manipulation (2,13). 
Cunentiy the role of PAP is limited to initial detection of ex-
traprostatic extension of the adenocarcinoma where imaging 
studies such as transrectal ultrasonography (TRUS) or com-
puted tomography have been equivocal. PAP can also be used in 
monitoring patients with stage C and D adenocarcinoma who 
are on either radiotherapy or hormonal therapy. 
Prostate-Specific Antigen 
PSA, a glycoprotein of the serine protease group similar to 
kaltikrein, has a molecular weight of 33,000 daltons and is a 
much smaller molecule than PAP (16). Produced by the prostat-
ic acinar epithelium, PSA has been located ultrastructurally in 
the rough endoplasmic reticulum and is stored in vesicles and 
vacuoles (3). PSA production is thought to be androgen-de-
pendent (17-19). Physiologically, PSA liquifies the semen, de-
grading the seminal vesicular proteins. In 1971 Hara et at (20) 
first isolated the protein from human semen and called it gamma 
seminoprotein. Wang and coworkers (16) extracted the protein 
from human prostate and termed it prostate-specific antigen. In 
1980 Papsidero et al (21) isolated the same antigen from the se-
mm of prostate cancer patients. Since then, many studies have 
shown its assay to be useful in diagnosis, screening, staging, and 
monitoring of prostate cancer (22-28). Several studies have con-
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Stage 
Table 1 
Clinical Staging of Prostate Cancer 
Definition 
A Incidental cancer 
A1 < 5% of tissue (Gleason < 4) 
A2 > 5% of tissue (Gleason > 4) 
B1 Palpable nodule extending into < 50% of one lobe 
B2 Palpable nodule larger than B1, limited to one lobe 
B3 Bilateral palpable cancer 
C Palpable cancer extending into one or both seminal vesicles 
DI Positive pelvic lymph nodes 
D2 Skeletal or vi,sceral metastasis 
Table 2 
BPH and Incidence of Raised PSA > 10 ng/mL 
Reference 
Number of Patients with Raised 
PSA> 10 ng/mL 
Hudson etal (28) 3 of 168 (2%) 
Myrtle et al (37) 7 of 352 (2%) 
Ercole et al (38) 10 of 357 (3%) 
Oesterling et al (39) 7 of 72 (10%) 
Cooner et al (40) 8 of 197 (4%) 
Henry Ford Hospital (unpublished data) 14 of 124 (11 %) 
firmed the identity of PSA and gamma seminoprotein (17,29). 
There are two assays currentiy available for PSA. The radiomet-
ric monoclonal antibody assay (Tandem-R, Hybritech) is the 
most widely used and has a normal range of 0.2 to 4.0 ng/mL 
(22,23,25-30). The polyclonal assay (Proscheck) developed by 
Yang (31) is also used by some investigators (15,24,32-36) and 
the normal range varies from 0.2 to 2.6 ng/mL. 
PSA and Benign Prostatic Hyperplasia 
The increase in glandular size characteristic of benign pros-
tatic hyperplasia (BPH) results in increased PSA production by 
the prostatic epithelium, Armitage et al (22) studied 139 patients 
with clinical BPH using the Tandem-R assay. Of the 121 pa-
tients with histologic diagnosis of BPH, the mean PSA was 5.9 
ng/mL, while in the 18 who were found to have latent cancer 
(stage A) mean PSA was 18.3 ng/mL. PSA levels were higher in 
men with larger prostate glands and those who presented with 
acute urinary retention had a mean PSA of 11.5 ng/mL, com-
pared to 3.8 ng/mL in those whose symptoms were only of 
prostatism, independent of the glandular size Morote et al (25) 
reported PSA levels > 10 ng/mL in more than 50% of BPH pa-
tients with acute urinary retention and indwelling catheters. 
Hudson et al (28) reported that only 21% of men with BPH have 
etevated PSA (> 4 ng/mL) and only 2% have PSA > 10 ng/mL. 
Table 2 shows the incidence of PSA > 10 ng/mL (Tandem-R) 
in several studies of BPH (28,37-40). Yang (31), using the 
Proscheck assay, found 62% of men with BPH to have PSA > 
2.5 ng/mL, and Stamey et al (15), using the same assay, found 
86% of 73 BPH patients to have elevated PSA (mean 7.9 ng/ 
mL). Observing the rate of fall of PSA after prostatectomy and 
relating it to the mass of resected adenomatous tissue, Stamey et 
al (15) concluded that BPH tissue elevates semm PSA level by 
0.3 ng/mL/g. However, Weber et al (18) could not demonstrate 
such a consistent conelation between serum PSA and the BPH 
tissue, probably because of the variable epithelial content in the 
hyperplastic glands. Prostatic intraepithelial neoplasia (PIN) 
has been shown to be responsible for the raised PSA in some 
BPH patients (41,42). Utilizing TRUS, Babaian et al (43) esti-
mated prostate gland volume in 408 men and found a statisti-
cally significant conelation of PSA with prostate volume and to 
a lesser degree with patient age. In our study of 124 patients uti-
lizing TRUS and PSA, we found a linear relationship between 
gland volume and PSA (unpublished data). 
While BPH does clearly elevate semm PSA, clinical applica-
tion of this correlation must be judiciously employed. While 
there seems to be a volume-dependent linear correlation be-
tween PSA and BPH tissue, levels above 10 ng/mL are infre-
quent in BPH, Therefore, PIN and occult CAP must also be con-
sidered as contributing factors for elevated PSA in patients with 
presumed BPH. 
Effect of Prostate Manipulation on PSA 
Yuan and Catalona (44) studied the relationship of PSA, 
DRE, prostatic massage TRUS, and needle biopsy. DRE had no 
influence on 5- and 90-minute post-DRE PSA levels. Only 5% 
of patients had elevated PSA after massage and 8% after TRUS, 
but PSA was elevated in 89% after needle biopsy (5 minutes) 
and in a third of those it remained high even after two weeks. 
The postbiopsy rise in PSA occuned following multiple biop-
sies (more than four). Prostatic size, baseline PSA, and the pres-
ence of prostate cancer had no influence on persistence of raised 
PSA. However, using the Proscheck assay, Stamey et at (15) 
demonstrated a significant rise in PSA and PAP foltowing pros-
tate massage, cystoscopy, and biopsy. Inflammatory conditions 
of the prostate gland such as acute prostatitis also cause elevated 
PSA (29). 
PSA and Carcinoma of Prostate 
Since PAP was the standard tumor marker for CAP before 
PSA was available, earlier studies compared its efficacy to that 
of PAP. Stamey et al (15) compared PSA and PAP levels in 127 
untreated patients with CAP. PSA was raised above 2.5 ng/mL 
(Proscheck) in 122 (96%) patients, including 7 of 12 patients 
with stage A and all 115 patients with stages B to D. However, 
PAP was raised in only 57% of the patients; none with stage A, 
9% with B1,39% with B2,40% with B3,64% with C, and 96% 
with D2. Myrtle et al (37), who studied 553 CAP patients using 
Tandem-R assay, found raised PSA in 81% while only 43% had 
raised PAP. The increased sensitivity is present in early disease. 
For all stages of prostate cancer, PSA is elevated more fre-
quently than PAP, probably because its small molecular size 
readily permits diffusion across the basement membrane into 
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Table 3 
PSA Values for BPH and Organ-Confined CAP* 
Percentage of Patients with PSA in the Range of 
Total Patients < 4 ng/mL 4-10 ng/mL > 10 ng/mL 
Reference BPH CAP BPH CAP BPH CAP BPH CAP 
Hudson et al (28) 168 ll).5 79 38 19 26 2 36 
Lange et al (30) 357 31 IS 32 3 23 
Partin et al (45) 72 185 47 4.S 46 44 7 11 
597 310 75 43 22 37 3 20 
*.Adapted from Oesterling JE. Prostate specific antigen; A critical assessment of the most useful marker for adenocarcinoma of the 
prostate. J Urol 1991:145:907-23. 
the circulation. Stamey et al (24,32) showed a linear relationship 
of PSA between cancer volume and Gleason score. However, a 
consistent relationship between the PSA and poorly differenti-
ated tumors could not be confirmed by Partin et al (45). Stamey 
et al (32) evaluated changes in PSA values after radical prosta-
tectomy. Given PSA half-life (2.5 to 3 days), they concluded 
that cancerous tissue raises serum PSA by 3 ng/mL/g. 
Role of PSA in Screening 
Since PSA is an improved marker for CAP, interest in its pos-
sible role in screening is considerable. As previousty noted, the 
minimal elevations of PSA which are found in BPH patients 
cau.se difficulty. In an exhaustive review, Oesterling (29) com-
pared PSA values of patients with BPH to those of patients with 
localized (organ-confined) CAP (Tabte 3). As many as 43% of 
CAP patients had normal PSA (< 4 ng/mL) while 25% of pa-
tients with BPH had PSA > 4 ng/mL. tn patients with organ-con-
fined CAP, PSA > 4 ng/mL had a 64% diagnostic accuracy and 
PSA > to ng/mL had a 70% diagnostic accuracy. The positive 
predictive value (PPV) was 49% and 75% for PSA > 4 ng/mL 
and > 10 ng/mL, respectively. Thus, due to overlap with both 
BPH and inflammatory prostatic disease, PSA is not specific 
enough to be used alone for screening. 
Several investigators (26,27,33,46) have studied the use of 
PSA in conjunction with DRE and TRUS in early detection of 
CAP. Cooner et al (27) reported on 1,807 symptomatic patients 
seen in a urologic clinic. All were evaluated using PSA, DRE, 
and TRUS. Patients with hypoechoic lesions shown by TRUS 
had biopsies. When both DRE and TRUS were negative, biop-
sies were not performed regardless of the PSA level. When PSA 
was > 10 ng/mL in the presence of abnormal DRE, PPV ap-
proached 80%. For PSA level of 4 ng/mL with abnormal DRE, 
PPV fell to 45%. For PSA > 10 ng/mL with negative DRE, the 
PPV fell to 31 % (Table 4). Catalona et al (26) measured PSA in 
1,653 healthy men over 50 years of age, a tme screening study. 
Those who had PSA > 4 ng/mL had DRE and TRUS. Biopsies 
were performed for abnormal DRE and/or TRUS. Only 107 
(6%) had PSA of 4.0 to 9.9 ng/mL and 30 (2%) had PSA > 10 
ng/mL. Only 22% of those with PSA < 10 ng/mL who had bi-
opsy were shown to have CAP whereas 67% of those with PSA 
> to ng/mL had CAP. Twelve (32%) and 16 (43%) ofthese pa-
tients with CAP had normal DRE and TRUS, respectively, and 
would have been missed if these modalities were utilized alone. 
Multivariate analysis of PSA as the predictor of cancer (com-
pared to Oiat of age, DRE, and TRUS) disclosed that PSA had 
significant predictive ability. Lee et al (46) examined 256 men 
who had hypoechoic lesions demonstrated by TRUS, 106 
(41%) of whom had CAP. Positive DRE and raised PSA (> 2.6 
ng/mL, Proscheck) in these patients had a PPV of 71 % for CAP 
(Table 5) (33). Raised PSA had greater diagnostic significance 
than positive DRE. However, Brawer and Lang (47) noted a 
32% false-negative rate (PSA < 4 ng/mL) and 58% of the can-
cers would have been missed if 10 ng/mL had been cho.sen as the 
cutoff level. In 54 unsetected CAP patients studied at Henry 
Ford Hospital, 22%. had PSA < 4 ng/mL and would therefore 
have been misdiagno.sed by the test. Due to the poor specificity 
of PSA, several other parameters have been suggested to aid 
early detection of CAP. Prostate-specific antigen density 
(PSAD), defined as the ratio of PSA over prostate volume, has 
been suggested (48,49). We analyzed 335 patients who under-
went TRUS for suspicious DRE or an elevated PSA (> 4 ng/mL) 
and found that a PSAD of 0.12 had the best efficacy values (sen-
sitivity, specificity, positive and negative predictive value) for 
the PSA range of 4 to 10 ng/mL (unpublished data. Table 6). 
PSAD > 0.15 has been suggested by other investigators (50). 
Another suggested parameter for early detection of CAP is ris-
ing PSA level. Stamey (34) recommends annual PSA testing in 
those with borderline levels, for rising PSA titers should alert 
the physician to a malignant process in the prostate. 
Although PSA is raised in many patients with localized CAP, 
its use in screening cannot be justified because of its high false-
negative rate, as well as the poor PPV for patients with lower 
range elevations. However, a combination of PSA and DRE 
with or without TRUS improves the detection rate of CAP. 
PSA in Staging 
Despite a linear conelation between PSA and pathological 
stage the use of PSA for preoperative staging is limited by the 
overlap of levels between stages. PSA levels of > 10 ng/mL 
were found in 11 % to 23% of patients with organ-confined CAP 
(29,45). However, using the Proscheck assay, Stamey et al (32) 
reported that patients with PSA < 10 ng/mL have little chance 
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Table 4 
Positive Predictive Value of DRE and PSA* 
Digital Rectal Examination 
PSA + 
-
< 4 ng/mL 16.9% 9.3% 
4 to 10 ng/mL 45% 20% 
> 10 ng/mL 76.7% 30.9% 
*Adapted from Cooner WH, Mosely BR, Rutherford CL Jr, et al. Clinical application of 
transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J 
Urol 1988;139:758-61. 
-I- = Abnormal on DRE (nodule, induration, asymmetry). 
— = Prostate with normal consistency. 
Table 5 
Positive Predictive Value for a Hypoechoic 
Lesion on TRUS* 
Digital Rectal Examination 
PSA (Proscheck) + -
> 2.6 ng/mL 71 '/< 34% 
0.2 to 2.6 ng/mL 26% 5% 
•Adapted from l^e F, Torp-Pedersen ST. Littrup PJ. et al. Hypoechoic lesions of the 
prostate: Clinical relevance of tumor size, digilal rectal examination, and prostate-specific 
antigen. Radiology 1989:170:29-32. 
for seminal vesicle and lymph node involvement. On the other 
hand, patients with PSA > 50 ng/mL canied a 90% chance of 
lymph node involvement. Oesterling et al (39) found that the 
false-positive rate of PSA as predictor of extracapsular penetra-
tion was 74% and 65% for a cutoff level of 4 and 10 ng/mL, re-
spectively. The ratio of polyclonal to monoclonal assay values 
in the same patient has been reported to predict lymph node in-
volvement (51). The ability of PSA to predict skeletal metastasis 
has been studied by Chybowski et al (52) who found that PSA < 
20 ng/mL had a negative predictive value of 99,7%. Similarly, 
the negative accuracy of PSA < 20 ng/mL was 92%. These re-
sults suggest that the expensive isotope bone scan may be un-
necessary in CAP patients with PSA < 20 ng/mL. 
PSA in Monitoring CAP 
Considering the half-life of PSA (2.5 to 3 days), semm levels 
should be undetectable three weeks after radical prostatectomy 
(29,30). Persistentiy raised PSA after this period suggests resid-
ual benign or malignant prostatic tissue Stamey et al (32) 
showed that 95% of patients with elevated PSA three to six 
months after radical prostatectomy had positive margins, semi-
nal vesicle involvement, or lymph node disease. Lange et al (30) 
performed anastomotic biopsy on patients with raised PSA three 
to six months after surgery. Although none had detectable resid-
ual or recunent disease, 39% were shown to have biopsy-posi-
tive local disease. Local adjuvant radiotherapy has been advo-
cated for those with raised PSA after radical prostatectomy. 
Stamey et al (35), studying 183 patients who received radio-
therapy for localized disease, observed that only 11 % had unde-
tectable PSA at a mean of 5 years posttreatment. Most of the pa-
tients (82%) showed a rapid fall of PSA during the first year, but 
in only 8% did the fall continue beyond one year. Rising PSA 
tevels, seen in 51 % of the 80 patients followed for more than one 
year, conelated with the development of skeletal metastasis and 
positive prostate biopsy. However, patients who develop D2 
disease foltowing radiotherapy for local disease have much 
lower PSA levels than do those with unti-eated D2 disease (35). 
The response of PSA to antiandrogen therapy is more dra-
matic than that to radiotherapy. Stamey et al (36) suggest that 
the PSA level six months after beginning hormonal therapy is 
prognostic of whether the patient would respond favorably to 
the treatment. In addition to the antitumor effect of hormonal 
therapy, androgen-dependent PSA deregulation may be respon-
sible for the rapid fall. Rising PSA in patients with CAP sug-
gests progression and the need for further therapy. 
Summary 
Although PSA is considered to be the true serum marker of 
prostatic tissue and a valuable indicator for cancer in the gland, 
knowledge of its significance and limitations is essential to its 
use for screening, staging, and monitoring CAP. PSA may be 
Table 6 
Efficacy of Various PSAD Values in DiiTerentiating 
BPH and CAP in PSA Range of 4 to 9.9 ng/mL 
0.08 0.10 
PSAD Values 
0.12 0.15 0.2 
Sensitivity 97% 9(1''/; 87% 70% 53% 
Specificity 28% 48% 60% 71% 86% 
Positive predictive value 27% 32% 37% 40% 50% 
Negative predictive value 97% 95% 94% 90% 87% 
Sensitivity: True positive (TP)A'P + fal.se-negative (FN). 
Specificity: True negative (TN)/TN false-positive (FP). 
Positive predictive value: TP/TP + FP. 
Negative predictive value: TN/TN -i- FN. 
Diagnostic accuracy: TP + TNATP -i- TN -i- FP -(- FN. 
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used in conjunction with DRE for eariy detection of CAP. Men 
with abnormal DRE should have a TRUS with or without bi-
opsy. In men older than 50 years and with negative DRE and 
PSA < 4 ng/mL, annual evaluations are prudent. In patients with 
a PSA range of 4.0 to 9.9 ng/mL, high-risk groups such as black 
males and those with a positive family history should have 
TRUS. Males with negative DRE in the PSA range of 4.0 to 9.9 
ng/mL should have TRUS to evaluate prostate volume and 
PSAD. Biopsy should be considered in those with PSAD > 0.15. 
Men with PSA > 10 ng/mL, even in the presence ofan enlarged 
benign prostate, should have multiple directed biopsies under 
TRUS guidance. 
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